ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance
May 9, 2019 8:30 AM EDTBAUDETTE, Minn., May 9, 2019 /PRNewswire/ --
For the first quarter 2019:
Net revenues of $52.9 million, an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share of $0.04 Record adjusted non-GAAP EBITDA of $22.3 million Adjusted non-GAAP diluted earnings per share of $1.30ANI Pharmaceuticals, Inc. ("ANI")Â (NASDAQ: ANIP) today reported its financial results for the three months ended March 31, 2019 and reaffirmed its 2019 financial guidance. The Company will host its earnings conference call this morning, May 9,... More
